TriangleTrabedersen (NCT06579196)
Trabedersen trial for Non-small Cell Lung Cancer (NCT06579196). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
Lung cancer is America's leading cancer killer. When tumors carry the marker PD-L1, treatment now starts with pembrolizumab, which takes the brakes off the immune system. It helps some; most tumors find a way through.
One way is a molecule called TGF-beta two, which tumors pour out to tell immune cells to stand down.
The idea: cut off that molecule while pembrolizumab does its work.
Trabedersen is a short strand of synthetic DNA that binds the instructions for TGF-beta two so they cannot be read. It has been tried before, in pancreatic cancer and glioma.
This trial, at the University of Nebraska with Omar Abughanimeh, gives it by infusion with pembrolizumab, and asks first what dose is safe. Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.